U.S., April 2 -- ClinicalTrials.gov registry received information related to the study (NCT07505771) titled 'A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Cancer' on March 18.
Brief Summary: IM-3050-101 is a Phase 1 study to determine the safety and effectiveness of 177Lu-IM-3050 in treating participants with advanced cancer.
Study Start Date: April, 2026
Study Type: INTERVENTIONAL
Condition:
Solid Malignancies
Intervention:
DRUG: 177Lu-IM-3050
177Lu-IM-3050 is a FAP-directed radiopharmaceutical
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Immunome, Inc.
Published by HT Digital Content Services with permission from Health Daily Digest....